HR Execs on the Move

EIP Pharma

www.eippharma.com

 
EIP Pharma is a private, clinical-stage therapeutics company focused on CNS disorders headquartered in Cambridge, Mass. EIP Pharma was launched in 2014 by R&D executives from the pharmaceutical and biotech industry who believed that emerging science supported exploring neflamapimod in Alzheimer’s disease.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details
John Alam
Chief Executive Officer Profile

Similar Companies

Glenmark Generics Limited

Glenmark Generics Limited is a Mahwah, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sonic Packaging Industries

Sonic Packaging Industries is a Westwood, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Global Napi Pharmaceuticals

Global Napi Pharmaceuticals is a Th October Egypt, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Beam Therapeutics

Beam Therapeutics, launched in 2018, is pioneering the use of CRISPR base editing to develop a broad portfolio of advanced genetic medicines. Our groundbreaking base editing technology allows us to make permanent, specific edits to single bases in DNA and RNA, without cutting the strands. Base editor therapeutics represent a new class of “precision genetic medicines,” combining precision targeting of the genome with precision control of editing outcomes. Our dream is to provide life-long cures for patients suffering from serious diseases. The Beam Team Is: • A community of fearless innovators • Rigorous and honest in our research • Listening with open minds • Committed to each other

Edgewise Therapeutics

Edgewise Therapeutics is a biotechnology company harnessing proven expertise and understanding of skeletal muscle physiology to develop novel, transformative therapies for serious muscle diseases. Based in Boulder, Colorado, we have built a state-of-the-art muscle research facility to capitalize on new insights into the nature and consequences of muscle adaptation and injury with disease. Edgewise recently closed it`s Series B financing round which will support the advancement of Edgewise Therapeutic`s lead product candidate into clinical development for Duchenne and Becker Muscular Dystrophy (DMD and BMD) as well as expansion of the company`s pipeline. The company`s leadership team has founded multiple biotechnology startups, several of which have gone on to become publicly-traded companies and brings to bear a depth of experience in drug discovery, development and commercialization.